glp-1 for mash Why are agonists being used to treat patients with nonalcoholic fatty liver disease? How to Use a GLP-1

The drug recently showed very promising early Phase II data in MASH, a liver disease closely associated with obesity

Retnakaran and colleagues say their data indicate that combining a GLP-1 agonist with basal insulin can achieve the ideal triumvirate of short-term outcomes in diabetes management: potent glucose-lowering capacity without increased hypoglycaemia or weight gain

10.1093/intimm/dxh186 Int Immunol

Innovations are expected to focus on safety, efficacy, affordability and convenience (oral applications, auto injectors etc)

Briefly, cells were sequentially treated with the medium containing 25 M of CldU (Sigma-Aldrich, C6891) and then 250 M of IdU (Sigma-Aldrich, I7125) for 20 min